• Home
  • About Us
  • Science
    • Active Immunotherapies
    • Antibodies
  • Our Pipeline
  • News
  • Investors
    • Share Info
    • Financial Info
    • Documents & Presentations
    • Corporate Governance
  • Publications
  • Contact Us
    • Find a trial
    • Become an Investigator

Scancell Circular 11th March 2016

by admin | Mar 11, 2016 | Circulars

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Recent Posts

  • ESMO IO: Refining Standard of Care in Advanced Melanoma
  • CEO Phil L’Huillier gives Report on Melanoma trial success to Proactive
  • SCOPE Data Update: 11 December 2025
  • European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 10-12 December 2025 in London
  • Latest SCOPE data confirm durable improvement

Recent Comments

No comments to show.

Scancell is focused on developing novel immunotherapies for the treatment of cancer and was founded in 1996 based on research led by Professor Lindy Durrant at the University of Nottingham in the UK.

  • Follow
  • Follow

About Us
Leadership Team
Science
Our Pipeline
News
Contact Us
Find a Trial
Become an Investigator

ACTIVE IMMUNOTHERAPY

ImmunoBody®
Moditope®

ANTIBODIES

GlyMab®
AvidiMab®

Investors
Company Profile
Advisors
Corporate Governance
Documents & Presentations
Share Information
Financial Information

Copyright © 2026 Scancell | Website Designed & Developed by Identity Creative | Privacy & Cookie Policy